Literature DB >> 9018094

Interferon potentiates antiproliferative activity of CPT-11 against human colon cancer xenografts.

S Ohwada1, I Kobayashi, M Maemura, Y Satoh, T Ogawa, Y Iino, Y Morishita.   

Abstract

We studied the antiproliferative effect of recombinant human interferon-alpha/beta/gamma (rHuIFN-alpha/beta/gamma) and CPT-11 against human colon cancer xenografts in nude mice. CPT-11 (25 mg/kg) alone exhibited significant antiproliferative effects. Although rHuIFN-alpha/beta/gamma alone did not show antiproliferative activity, it markedly enhanced the antiproliferative activity of CPT-11. rHuIFN-alpha/beta/gamma significantly increased in the population of cells in the S-phase. rHuIFN-alpha/beta/gamma progressed cell cycle in the S-phase under the existence of CPT-11, which exhibited no effect on cell cycle progression. Because CPT-11 is known to exhibit antiproliferative effect on S-phase cells, IFNs, especially rHuIFN-alpha and beta, can enhance the antiproliferative effect of CPT-11 mediated by cell accumulation in the S-phase.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9018094     DOI: 10.1016/s0304-3835(96)04477-1

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  9 in total

1.  Systemic IFN-beta gene therapy results in long-term survival in mice with established colorectal liver metastases.

Authors:  H Tada; D J Maron; E A Choi; J Barsoum; H Lei; Q Xie; W Liu; L Ellis; A D Moscioni; J Tazelaar; S Fawell; X Qin; K J Propert; A Davis; D L Fraker; J M Wilson; F R Spitz
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

2.  Oncolytic vaccinia virus synergizes with irinotecan in colorectal cancer.

Authors:  Kathryn Ottolino-Perry; Sergio A Acuna; Fernando A Angarita; Clara Sellers; Siham Zerhouni; Nan Tang; J Andrea McCart
Journal:  Mol Oncol       Date:  2015-05-06       Impact factor: 6.603

3.  Chemosensitivity is controlled by p63 modification with ubiquitin-like protein ISG15.

Authors:  Young Joo Jeon; Mi Gyeong Jo; Hee Min Yoo; Se-Hoon Hong; Jung-Mi Park; Seung Hyeun Ka; Kyu Hee Oh; Jae Hong Seol; Yong Keun Jung; Chin Ha Chung
Journal:  J Clin Invest       Date:  2012-06-18       Impact factor: 14.808

4.  ISG15 as a novel tumor biomarker for drug sensitivity.

Authors:  Shyamal D Desai; Laurence M Wood; Yu-Chen Tsai; Tao-Shih Hsieh; Jeffrey R Marks; Georgia L Scott; Beppino C Giovanella; Leroy F Liu
Journal:  Mol Cancer Ther       Date:  2008-06       Impact factor: 6.261

5.  ISG15 silencing increases cisplatin resistance via activating p53-mediated cell DNA repair.

Authors:  Yi Huo; Zhaoyun Zong; Qingtao Wang; Zhenyu Zhang; Haiteng Deng
Journal:  Oncotarget       Date:  2017-11-18

Review 6.  ISG15 and immune diseases.

Authors:  Young Joo Jeon; Hee Min Yoo; Chin Ha Chung
Journal:  Biochim Biophys Acta       Date:  2010-02-12

Review 7.  Modification by ubiquitin-like proteins: significance in apoptosis and autophagy pathways.

Authors:  Umar-Faruq Cajee; Rodney Hull; Monde Ntwasa
Journal:  Int J Mol Sci       Date:  2012-09-19       Impact factor: 6.208

8.  Pharmacological targeting of NF-kappaB potentiates the effect of the topoisomerase inhibitor CPT-11 on colon cancer cells.

Authors:  P Lagadec; E Griessinger; M P Nawrot; N Fenouille; P Colosetti; V Imbert; M Mari; P Hofman; D Czerucka; D Rousseau; E Berard; M Dreano; J F Peyron
Journal:  Br J Cancer       Date:  2008-01-08       Impact factor: 7.640

Review 9.  ISG15 in the tumorigenesis and treatment of cancer: An emerging role in malignancies of the digestive system.

Authors:  Chaohui Zuo; Xinyi Sheng; Min Ma; Man Xia; Linda Ouyang
Journal:  Oncotarget       Date:  2016-11-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.